-
.jpg)
- ESMO 2023 포스터
- An open-label, multicenter, phase 1/2 study of GI-101, CD80-IgG4 Fc-IL2v, in advanced solid tumors(Part A of GII-101-P101; KEYNOTE-B59)
-
.jpg)
- SITC 2022 포스터
- Preliminary results of GII-101-P101 (Keynote-B59): GI-101 (CD80-IgG4 Fc-IL2v) as a single agent and in combination with pembrolizumab in patients with advanced and/or metastatic solid tumors
-
.jpg)
.jpg)
- SITC 2021 포스터
- A phase 1/2, open-label, dose escalation and expansion study of GI-101 as a single agent and in combination with a Pembrolizumab, Lenvatinib or Local RT in advanced solud tumors (KEYNOTE-B59)
-
.jpg)
- AACR 2021 포스터
- Comprehensive preclinical study on GI-101, a novel CD80-IgG4-IL2 variant protein, as a therapeuticantibody candidate with bispecific immuno-oncology target
-
.jpg)
- AACR 2020 포스터
- GI101, A novel CD80-IgG4-IL2 variant bispecific protein, inhibits tumor growth and induces anti-tumor immune response in multiple preclinical models
-
.jpg)
- ESMO 2019 포스터
- GI101, a novel triple-targeting bispecific CD80-IgG4-IL2 variant fusion protein, elicits synergistic anti-tumor effects in preclinical models
-
.jpg)
.jpg)
- UCARE CONFERENCE 2019 포스터
- GI-301: a novel long-acting IgE Trap-Fc fusion protein for IgE-mediated allergic diseases
구독 신청을 작성하시면
지속적인 소식을 받아 보실 수 있습니다.
지속적인 소식을 받아 보실 수 있습니다.